Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





BD Presents Latest Automated Solutions to Combat Antimicrobial Resistance at ECCMID 2022

By LabMedica International staff writers
Posted on 26 Apr 2022

Becton, Dickinson and Company (BD Franklin Lakes, NJ, USA) presented its latest automation solutions for clinical laboratories, which may play a critical role in the fight against infectious diseases and antimicrobial resistance at ECCMID 2022. More...

BD showcased its Kiestra lab automation solutions that provide total lab automation for the clinical microbiology lab through modularity, scalability and open architecture. These solutions are designed to increase efficiency, streamline processes, and deliver high quality and consistent results with improved turnaround time. BD Kiestra lab automation offerings include complementary and modular microbiology workflow automation solutions, ranging from standalone units to fully automated track-based automation systems for mid- and high-volume labs.

On display was the BD Kiestra IdentifA solution, which is available as part of a track-based BD Kiestra laboratory automation solution, and supports specimen preparation workflows for routine and challenging isolate types in combination with identification on the BD Bruker MALDI Biotyper. The BD Kiestra IdentifA solution helps bring accuracy and efficiency to preparing samples for microbial identification. By automating the sample processing steps required to identify a microorganism, this solution helps reduce potential for user error while providing clinicians with bacterial identification for a patient suspected of having an infection.

BD also demonstrated its BACTEC FX blood culturing instruments used with patented resin-containing media have shown higher rates of organism recovery, allowing for proper diagnosis and treatment of bloodstream infections. The BD BACTEC FX builds on the proven superior fluorescence detection technology, exceptional media performance and instrument reliability of the BD BACTEC 9000 blood culture systems. Also on display at the event was the BD MAX System, a fully-integrated, automated platform that performs nucleic acid extraction and real-time PCR providing results for up to 24 samples across multiple syndromes in less than three hours.

Related Links:
Becton, Dickinson and Company 


Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
POC Immunoassay Analyzer
Procise DX
Prefilled Tubes
Prefilled 5.0ml Tubes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Molecular Diagnostics

view channel
Image: MCD tests are designed to detect multiple cancers from a single blood sample, but the statements note that evaluating these assays is far more complex than assessing single-cancer tests (image credit: Adobe Stock)

Position Statements Outline Evidence Standards for Multi-Cancer Detection Tests

Cancer screening is intended to reduce mortality, but policy decisions often depend on early indicators that may not fully reflect true survival benefit. The emergence of blood-based tests capable of detecting... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.